Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Biotechnology

Healthcare
$5.08 -2.45%

-$0.27 today

Market cap
$412.96M
Beta
0.51
P/E (TTM)
-5.6
EPS (TTM)
-$1.92
52W Low $7.61High $18.31

Volume 1.03M

Average 1.21M

Income Statement

Follow revenue through to earnings.

Revenue

$175.11M

FY 2025 · Annual

+216.9% YoY

Operating Income

-$159.99M

FY 2025 · Annual

Net Income

-$221.25M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00682K55.25M175.11M
Cost of Revenue521K620K167K7.97M22.6M
Gross Profit(521K)(620K)515K47.28M152.51M
Gross Margin——75.5%85.6%87.1%
Research & Development72.34M71.44M49.9M34.08M32.78M
Selling, General & Admin62.22M100.38M117.93M290.66M279.72M
Operating Expenses134.56M171.82M167.83M324.75M312.5M
Depreciation & Amortization521K620K575K795K633K
EBITDA(136.57M)(169.8M)(159.05M)(261.52M)(152.5M)
EBITDA Margin——-23321.0%-473.3%-87.1%
Operating Income(135.08M)(172.44M)(167.31M)(277.47M)(159.99M)
Operating Margin——-24532.6%-502.2%-91.4%
Interest Income41K2.13M7.88M15.16M7.04M
Interest Expense6.79M27.31M41.97M72.01M68.12M
Other Income / Expenses(8.8M)(25.28M)(34.28M)(56.86M)(61.26M)
Income Before Tax(143.88M)(197.72M)(201.59M)(334.33M)(221.25M)
Pre-Tax Margin——-29558.9%-605.1%-126.3%
Income Tax Expense00000
Net Income(143.88M)(197.72M)(201.59M)(334.33M)(221.25M)
Net Margin——-29558.9%-605.1%-126.3%
EPS (Basic)(4.00)(5.70)(3.93)(5.29)(3.03)
EPS (Diluted)(4.00)(5.70)(3.93)(5.29)(3.03)
Weighted Avg Shares37M39.12M51.29M63.18M72.92M
Weighted Avg Shares (Diluted)37M39.12M51.29M63.18M72.92M

PHAT Earnings Waterfall · TTM

NASDAQ:PHAT · Revenue to Net Income

Key Ratios

EPS$-2.12
Gross Margin85.2%
Net Margin-85.3%
P/E Ratio-7.9
P/S Ratio18.0

Analysis

$204.9M of revenue converted into -$157.3M of net income for the selected period. Gross margin is 85.2% and net margin is -85.3%, showing how much revenue survives after costs and taxes. EPS is $-2.12, tying the income statement back to per-share earnings.

Competitors

Peer companies in the same sector

Health

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 10, 2026
SC 13D/ASC 13D/A filingNov 2, 2026
10-QQuarterly reportOct 29, 2026
8-KCurrent reportOct 29, 2026
8-KCurrent reportOct 26, 2026

How much revenue does PHAT generate?

Phathom Pharmaceuticals, Inc. (PHAT) reported $175.11M of revenue in fiscal 2025.

Is PHAT profitable?

Phathom Pharmaceuticals, Inc. (PHAT) reported -$221.25M of net income, with a net margin of -126.3%.